425: Quanterix Announces Q4 2024 Financial Results and Akoya Biosciences Acquisition

Quanterix reports an 11% revenue increase for Q4 2024 and highlights the pending acquisition of Akoya Biosciences.

Summary

• Quanterix Corporation announced its financial results for the fourth quarter and full year ended December 31, 2024.
• Q4 revenue increased by 11% to $35.2 million compared to $31.5 million in the prior year.
• GAAP gross margin for Q4 was 63.0%, up from 61.5% in the prior year.
• The net loss for Q4 was $11.6 million, compared to a net loss of $8.8 million in the prior year.
• Net cash usage during the quarter was $4.4 million, compared to $6.4 million in the prior year.
• The company ended 2024 with $291.7 million in cash, cash equivalents, marketable securities, and restricted cash.
• Full year 2024 revenue increased by 12% to $137.4 million compared to $122.4 million in the prior year.
• The net loss for the full year was $38.5 million, a decrease of $10.2 million compared to the prior year.
• Net cash usage for the full year was $32.2 million, compared to $17.4 million in the prior year.
• Quanterix expects 2025 revenue to be in the range of $140.0 million to $146.0 million, representing growth of 2% to 6% over 2024.
• The company anticipates 2025 cash usage to be approximately $55.0 million to $65.0 million, including $20.0 million of upfront payments for the EMISSION acquisition.
• Quanterix announced a definitive merger agreement to acquire Akoya Biosciences in an all-stock transaction, expected to close in the second quarter of 2025.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook, highlighting revenue growth, strategic acquisitions, and new product launches. However, the net losses and increased cash usage temper the overall sentiment.

Positives

• Quanterix achieved its seventh consecutive quarter of double-digit revenue growth.
• The company's GAAP gross margin improved in Q4 2024.
• Quanterix ended 2024 with a strong cash position.
• The company is launching Simoa ONE, promising a 10-fold increase in sensitivity.
• Quanterix acquired EMISSION to secure the supply of beads for its next-generation Simoa ONE platform.
• Quanterix received Breakthrough Designation from the FDA for LucentAD Complete.
• The planned acquisition of Akoya Biosciences is expected to create an integrated solution for biomarker detection.

Negatives

• Quanterix reported a net loss of $11.6 million for Q4 2024, compared to a net loss of $8.8 million in the prior year.
• Net cash usage increased for the full year 2024 compared to the prior year.
• The company's 2025 revenue growth forecast of 2% to 6% is relatively modest.

Risks

• The company's estimates regarding expenses, future revenues, capital requirements, and needs for additional financing could be incorrect.
• There are risks related to the restatement of Quanterix's consolidated financial statements, including increased costs and the possibility of legal proceedings.
• Quanterix faces risks related to its ability to maintain effective internal control over financial reporting.
• The anticipated benefits and synergies of the Merger with Akoya may not be realized.
• The Merger may be more expensive to complete than anticipated.
• The company's share price could be affected before the closing of the Merger.
• There are risks relating to the potential dilutive effect of shares of Quanterix common stock to be issued in the Merger.

Future Outlook

Quanterix expects 2025 revenue to be in the range of $140.0 million to $146.0 million, representing growth of 2% to 6% over 2024, and anticipates 2025 cash usage to be approximately $55.0 million to $65.0 million. The acquisition of Akoya Biosciences is expected to close in the second quarter of 2025.

Management Comments

• Masoud Toloue, Chief Executive Officer of Quanterix, stated that the company delivered 11% revenue growth in Q4 despite a capital constrained environment.
• He attributed the growth to investments in the business model, focusing on key vertical markets and recurring revenues.
• He highlighted the expansion into immunology and oncology to grow the addressable market.
• He emphasized that the acquisition of Akoya Biosciences is an important step forward in the execution of this strategy.

Industry Context

Quanterix operates in the ultra-sensitive biomarker detection market, which is experiencing growth due to increasing demand for early disease detection and personalized medicine. The acquisition of Akoya Biosciences positions Quanterix to offer a more comprehensive solution for bloodand tissue-based protein biomarker detection, potentially giving them a competitive edge. Competitors include companies like Illumina, Roche, and Thermo Fisher Scientific, which offer various solutions for biomarker analysis.

Comparison to Industry Standards

• Quanterix's revenue growth of 12% for the full year 2024 is comparable to other companies in the life sciences and diagnostics industry.
• For example, companies like Exact Sciences and Guardant Health have also reported double-digit revenue growth in recent years.
• Quanterix's gross margin of 60.5% is within the typical range for diagnostics companies, but may be lower than some companies with a higher proportion of proprietary products.
• The planned acquisition of Akoya Biosciences is similar to other strategic acquisitions in the industry aimed at expanding product portfolios and market reach.

Stakeholder Impact

• Shareholders can expect potential benefits from the acquisition of Akoya Biosciences and the launch of new products.
• Employees may experience changes related to the integration of Akoya Biosciences.
• Customers will have access to a more comprehensive solution for biomarker detection.
• Suppliers may see increased demand for components used in Quanterix's products.
• Creditors should be aware of the company's cash position and future cash usage plans.

Next Steps

• The company plans to launch Simoa ONE by the end of 2025.
• Quanterix and Akoya will seek stockholder approvals for the proposed merger.
• The companies will work to satisfy the closing conditions for the merger, with an expected closing in the second quarter of 2025.

Key Dates